Manager TitleAgeSince
Chief Operating Officer - 14/11/2022
Director TitleAgeSince
Director/Board Member 61 16/08/2005
Chairman 67 19/09/2014
Director/Board Member 56 05/06/2008
Change 5-day change 1-year change 3-year change Capi.($)
-23.37%-37.69% - - 1.28M
+1.76%+3.88%+46.85%+101.12% 69.69B
+2.29%+1.43%+38.39%+77.03% 61.24B
+1.14%-2.59%-14.37%+365.92% 26.77B
+0.32%+5.47%+27.74%+14.12% 26.12B
+2.95%+2.34%+0.52%-12.74% 24.07B
+1.49%+7.73%+26.85%-15.89% 20.39B
-0.83%-9.47%+174.16%+295.44% 15.72B
+3.01%+1.85%+44.63%+168.18% 14.07B
+0.17%-2.74%-9.79%+484.05% 14.03B
Average -1.11%-0.06%+37.22%+164.14% 30.23B
Weighted average by Cap. +1.60%+1.41%+35.81%+129.00%
Logo 4SC AG
4Sc AG is a Germany-based clinical-stage biopharmaceutical company that develops small-molecule drugs that target key indications in cancer through epigenetic mechanisms. The Company’s product pipeline includes several anti-cancer drugs, which are in various stages of preclinical and clinical development. Its main products are Resminostat, an orally administered histone deacetylase (HDAC) inhibitor for the treatment of a broad spectrum of oncology indications, both in monotherapy in combination with other anti-cancer drugs; 4SC-202, an orally administered small molecule and epigenetic modulator that inhibits the enzymes lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) 1, 2, 3, and 4SC-208, a small molecule that targets two kinases for Hedgehog/GLI signaling.
Employees
14
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!